Teva stock is a "Hold" as its "Pivot to Growth" strategy shows early promise but requires further execution. Click for more ...

Grail and Veeva Systems could be well insulated from near-term headwinds.

AmyriAD Therapeutics B.V. ("AmyriAD"), a clinical-stage biopharmaceutical company focused on cognition in central nervous system disorders, today announced the acquisition of Recognify Life Sciences, ...

Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...

Introduction"Patient X is becoming agitated and looks like they are about to pull out their IV. Please give me orders to calm ...

It is being developed by LB Pharma for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders, and has ...

Microsoft remains a buy as core business indicators, especially Azure, show robust growth and momentum. Learn why MSFT stock ...

The music world lost Bob Weir in January, and Dolly Parton in September. Two legends gone. Two icons who were taken from the world due to the horrific disease that is cancer. And, sadly, the list of ...

What makes a great compounder? Michael Carmody, Jun Bei Liu and two other fundies reveal their ASX picks that can keep on ...

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into their prices.

CVRx stock (ISIN US1266381052) gained 3.85 percent to close at USD 1.62 on Nasdaq on October 6, 2026. The next company ...